{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-017054","form_type":"8-K","ticker":"ASBP","cik":"0001847345","company_name":"Aspire Biopharma Holdings, Inc.","filed_at":"2026-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.116698+00:00","generated_at":"2026-05-15T05:51:33.708009+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aspire Biopharma shareholders approve reverse stock split and authorized share increase","bullets":["Reverse stock split ratio range 1:5 to 1:500 approved: 2,096,356 for, 582,185 against, 12,852 abstain.","Authorized common stock increase from 490M to 700M shares passed: 1,925,368 for, 524,501 against, 7,403 abstain.","Series A Preferred issuance for conversion shares and floor price approved: 1,466,141 for, 203,756 against, 8,652 abstain, 1,012,844 broker non-votes.","ELOC Agreement share issuance approved: 1,469,985 for, 203,926 against, 4,638 abstain, 1,012,844 broker non-votes."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-017054","json":"https://secwatch.observer/filing/0001493152-26-017054.json","markdown":"https://secwatch.observer/filing/0001493152-26-017054.md","text":"https://secwatch.observer/filing/0001493152-26-017054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226017054/0001493152-26-017054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226017054/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:51:33.708009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}